Induction of HCV-specific cell response in vitro by dendritic cells generated with interferon-α

Cover Page


Cite item

Full Text

Abstract

The induction of a strong multi-epitope T-cell response against hepatitis C virus (HCV) plays an important role in eliminating the virus, whereas adoptive response deficiency contributes to chronic and rapid progression of HCV-infection. Since dendritic cells (DCs) are capable of priming naive T lymphocytes and induce an effective immune response, the use of DC-based vaccines to enhance the HCV-specific T cell response is considered as a new approach to treatment of chronic hepatitis C (CHC). The ability of DCs generated from monocytes in the presence of interferon-α and loaded with recombinant HCV proteins Core (1–120) and NS3 (1192–1457) to induce an antigen-specific cellular response in healthy donors and patients with CHC was investigated. The immune response was assessed by proliferative activity and Th1 (IFNγ)/Th2 (IL-4, IL-6) production in mononuclear cells (MNC) cultures, and activation of cytotoxic T-lymphocytes in the degranulation test. We demonstrated that the primary antigen-specific response in MNC cultures of seronegative donors was detected better by stimulation of DCs, loaded with both antigens (DCCore /NS3) than when loaded with a single protein. DCCore/NS3  induced the proliferative response and degranulation of CD8+ T cells in MNC cultures of all tested donors, and in 50% (5/10) cases — IFNγ production. Similarly to donor DCs, DCCore/NS3 of patients with CHC induced a proliferative response in most cases (86%) and IFNγ production in 57% cases. At the same time, the activation of cytotoxic T cells in patients was less frequent (patients vs donors 57 and 100%, respectively), which could be partly due to increased spontaneous degranulation of CD8+ T cells in some patients. The obtained data testify the possibility of using vaccines based on interferon-α-induced DCs for the prevention and treatment of chronic HCV infection.

About the authors

E. R. Chernykh

Research Institute of Fundamental and Clinical Immunology

Email: ct_lab@mail.ru

Chernykh Elena Removna - RAS Corresponding Member, PhD, MD (Medicine), Professor, Head of the Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology.

630099, Novosibirsk, Yadrintsevskaya str., 14.

Phone: +7 (383) 236-03-29. Fax: +7 (383) 222-70-28.

Россия

E. A. Oleynik

Research Institute of Fundamental and Clinical Immunology

Email: oleynik-90@bk.ru

Oleynik Ekaterina Alexandrovna - Postgraduate Student, Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology.

630099, Novosibirsk, Yadrintsevskaya str., 14.

Россия

O. Yu. Leplina

Research Institute of Fundamental and Clinical Immunology

Email: oleplina@mail.ru

Leplina Olga Yur’evna - PhD, MD (Medicine), Leading Researcher, Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology.

630099, Novosibirsk, Yadrintsevskaya str., 14.

Россия

M. A. Tikhonova

Research Institute of Fundamental and Clinical Immunology

Email: martix-59@mail.ru

Tikhonova Marina Alexandrovna - PhD (Biology), Senior Researcher, Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology.

630099, Novosibirsk, Yadrintsevskaya str., 14.

Россия

T. V. Tyrinova

Research Institute of Fundamental and Clinical Immunology

Email: tyrinova@bk.ru

Tyrinova Tamara Viktorovna - PhD (Biology), Researcher, Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology.

630099, Novosibirsk, Yadrintsevskaya str., 14.

Россия

N. M. Starostina

Research Institute of Fundamental and Clinical Immunology

Email: ct_lab@mail.ru

Starostina Natalya Mihaylovna - Honored Doctor of Russian Federation, PhD (Medicine), Head of the Immunology Department, Clinics of Immunopathology, Research Institute of Fundamental and Clinical Immunology.

630099, Novosibirsk, Yadrintsevskaya str., 14.

Россия

A. A. Ostanin

Research Institute of Fundamental and Clinical Immunology

Author for correspondence.
Email: ct_lab@mail.ru

Ostanin Alexander Anatolievich - PhD, MD (Medicine), Professor, Head Researcher, Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology.

630099, Novosibirsk, Yadrintsevskaya str., 14.

Россия

References

  1. Олейник Е.А., Леплина О.Ю., Тыринова Т.В., Тихонова М.А., Пыринова Г.Б., Останин А.А., Старостина Н.М., Черных Е.Р. Влияние рекомбинантных белков Core и NS3 вируса гепатита С на созревание и функции дендритных к леток, генерируемых in vitro в присутствии интерферона-альфа // Иммунология. 2016. Т. 37, № 5. С. 239–245.
  2. Carbonneil C., Aouba A., Burgard M., Cardinaud S., Rouzioux C., Langlade-Demoyen P., Weiss L. Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8T cells. AIDS, 2003, vol. 17, no. 12, pp. 1731–1740. doi: 10.1097/01.aids.0000076306.76477.15
  3. Dolganiuc A., Kodys K., Kopasz A., Marshall C., Do T., Romics L. Jr., Mandrekar P., Zapp M., Szabo G. Hepatitis C virus core and nonstructural protein 3 proteins induce proinf lammatory cytokines and inhibit dendritic cell differentiation. J. Immunol., 2003, vol. 170, no. 11, pp. 5615–5624. doi: 0.4049/jimmunol.170.11.5615
  4. Echeverria I., Pereboev A., Silva L., Zabaleta A., Riezu-Boj J.I., Bes M., Cubero M., Borras-Cuesta F., Lasarte J.J., Esteban J.I., Prieto J., Sarobe P. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology, 2011, vol. 54, no. 1, pp. 28–37. doi: 10.1002/hep.24325
  5. Eickhoff S., Brewitz A., Gerner M.Y., Klauschen F., Komander K., Hemmi H., Garbi N., Kaisho T., Germain R.N., Kastenmüller W. Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions. Cell, 2015, vol. 162, no. 6, pp. 1322–1337. doi: 10.1016/j.cell.2015.08.004
  6. Gessani S., Conti L., Del Corno M., Belardelli F. Type I interferons as regulators of human antigen presenting cell functions. Toxins (Basel), 2014, vol. 6, no. 6, pp. 1696–1723. doi: 10.3390/toxins6061696
  7. Guo Z., Zhang H., Rao H., Jiang D., Cong X., Feng B., Wang J., Wei L., Chen H. DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response. PLoS One, 2012, vol. 7, no. 6: e38390. doi: 10.1371/journal.pone.0038390
  8. Jin Z., Fan J., Zhang Y., Yi Y., Wang L., Yin D., Deng T., Ye W. Comparison of morphology, phenotypes and function between cultured human IL4DC and IFNDC. Mol. Med. Rep., 2017, vol. 16, no. 5, pp. 345–354. doi: 10.3892/mmr.2017.7581
  9. Kamal S.M., Fehr J., Roesler B., Peters T., Rasenack J.W. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology, 2002, vol. 123, no. 4, pp. 1070 –1083. doi: 10.1053/gast.2002.36045
  10. Koziel M.J. Cellular immune responses against hepatitis C virus. Clin. Infect. Dis., 2005, vol. 41, no. 1, pp. 25–31. doi: 10.1086/429492
  11. Krishnadas D.K., Ahn J.S., Han J., Kumar R., Agrawal B. Immunomodulation by hepatitis C virus-derived proteins: targeting human dendritic cells by multiple mechanisms. Int. Immunol., 2010, vol. 22, no. 6, pp. 491–502. doi: 10.1093/intimm/dxq033
  12. Lapenta C., Santini S.M., Spada M., Donati S., Urbani F., Accapezzato D., Franceschini D., Andreotti M., Barnaba V., Belardelli F. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur. J. Immunol., 2006, vol. 36, no. 8, pp. 2046–2060. doi: 10.1002/eji.200535579
  13. Lauer G.M., Barnes E., Lucas M., Timm J., Ouchi K., Kim A.Y., Day C.L., Robbins G.K., Casson D.R., Reiser M., Dusheiko G., Allen T.M., Chung R.T., Walker B.D., Klenerman P. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology, 2004, vol. 127, no. 3, pp. 924–936. doi: 10.1053/j.gastro.2004.06.015
  14. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Robbins G., Phillips R., Klenerman P., Walker B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med., 2000, vol. 191, no. 9, pp. 1499–1512. doi: 10.1084/jem.191.9.1499
  15. Leplina O.Y., Tyrinova T.V., Tikhonova M.A., Ostanin A.A., Chernykh E.R. Interferon alpha induces generation of semi-mature dendritic cells with high pro-inf lammatory and cytotoxic potential. Cytokine, 2015, vol. 71, no. 1, pp. 1–7. doi: 10.1016/j.cyto.2014.07.258
  16. Li W., Krishnadas D.K., Li J., Tyrrell D.L., Agrawal B. Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy. J. Immunol., 2006, vol. 176, no. 10, pp. 6065–6075. doi: 10.4049/jimmunol.176.10.6065
  17. Li W., Li J., Tyrrell D.L., Agrawal B. Expression of hepatitis C virus (HCV) derived Core or NS3 antigens in human dendritic cells leads to induction in pro-inf lammatory cytokines and normal T cell stimulation capabilities. J. Gen. Virol., 2006, vol. 87, pp. 61–72. doi: 10.1099/vir.0.81364-0
  18. Manns M.P., Wedemeyer H., Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut, 2006, vol. 55, no. 9, pp. 1350 –1359. doi: 10.1136/gut.2005.076646
  19. Mishra S., Losikoff P.T., Self A.A., Terry F., Ardito M.T., Tassone R., Martin W.D., De Groot A.S., Gregory S.H. Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naive human T cells. Vaccine, 2014, vol. 32, no. 26, pp. 3285–3292. doi: 10.1016/j.vaccine.2014.03.083
  20. Mohd Hanafiah K., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: new estimates of age specific antibody to HCV seroprevalence. Hepatology, 2013, vol. 57, no. 4, pp. 1333–1334. doi: 10.1002/hep.26141
  21. Neumann-Haefelin C., Blum H.E., Chisari F.V., Thimme R. T cell response in hepatitis C virus infection. J. Clin. Virol., 2004, vol. 32, no. 2, pp. 75–85. doi: 10.1016/j.jcv.2004.05.008
  22. Paquette R.L., Hsu N.C., Kiertscher S.M., Park A.N., Tran L., Roth M.D., Glaspy J.A. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol., 1998, vol. 64, no. 3, pp. 358–367. doi: 10.1002/jlb.64.3.358
  23. Petruzziello A., Marigliano S., Loquercio G., Cozzolino A., Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J. Gastroenterol., 2016, vol. 22, no. 34, pp. 7824–7840. doi: 10.3748/wjg.v22.i34.7824
  24. Rispeter K., Lu M., Behrens S.E., Fumiko C., Yoshida T., Roggendorf M. Hepatitis C virus variability: sequence analysis of an isolate after 10 years of chronic infection. Virus Genes, 2000, vol. 21, no. 3, pp. 179–188.
  25. Ruben J.M., Bontkes H.J., Westers T.M., Hooijberg E., Ossenkoppele G.J., de Gruijl T.D., van de Loosdrecht A.A. Differential capacity of human interleukin-4 and interferon-α monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen. Cancer Immunol. Immunother., 2015, vol. 64, no. 11, pp. 1419–1427. doi: 10.1007/s00262-015-1741-1
  26. Sachdeva M., Chawla Y.R., Arora S.R. Dendritic cells: the warriors upfront-turned defunct in chronic hepatitis C infection. World J. Hepatol., 2015, vol. 7, no. 19, pp. 2202–2208. doi: 10.4254/wjh.v7.i19.2202
  27. Saito K., Ait-Goughoulte M., Truscott S.M., Meyer K., Blazevic A., Abate G., Ray R.B., Hoft D.F., Ray R. Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J. Virol., 2008, vol. 82, no. 7, pp. 3320 –3328. doi: 10.1128/JVI.02547-07
  28. Schulze zur Wiesch J., Lauer G.M., Day C.L., Kim A.Y., Ouchi K., Duncan J.E., Wurcel A.G., Timm J., Jones A.M., Mothe B., Allen T.M., McGovern B., Lewis-Ximenez L., Sidney J., Sette A., Chung R.T., Walker B.D. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J. Immunol., 2005, vol. 175, no. 6, pp. 3603–3613. doi: 10.4049/jimmunol.175.6.3603
  29. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., Govindarajan S., Purcell R.H., Chisari F.V. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. USA, 2002, vol. 99, no. 24, pp. 15661–15668. doi: 10.1073/pnas.202608299
  30. Wilby K.J., Partovi N., Ford J.A., Greanya E., Yoshida E.M. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can. J. Gastroenterol., 2012, vol. 26, no. 4, pp. 205–210. doi: 10.1155/2012/751057
  31. Zhou Y., Zhang Y., Yao Z., Moorman J.P., Jia Z. Dendritic cell-based immunity and vaccination against hepatitis C virus infection. Immunology, 2012, vol. 136, no. 4, pp. 385–396. doi: 10.1111/j.1365-2567.2012.03590.x

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Chernykh E.R., Oleynik E.A., Leplina O.Y., Tikhonova M.A., Tyrinova T.V., Starostina N.M., Ostanin A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies